Syncom Formulations (India) Ltd's Q3FY25 Quarter Results
- 11 Feb 2025
Result Summary
- Syncom Formulations (India) Ltd reported a 23.6% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 88.8%.
- Its expenses for the quarter were up by 24.8% QoQ and 89.5% YoY.
- The net profit increased 17.0% QoQ and increased 85.7% YoY.
- The earnings per share (EPS) of Syncom Formulations (India) Ltd stood at 0.1 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 131.57 | 106.46 | 69.69 | 23.6% | 88.8% |
Total Expenses | 114.31 | 91.61 | 60.31 | 24.8% | 89.5% |
Profit Before Tax | 17.26 | 14.85 | 9.36 | 16.2% | 84.4% |
Tax | 4.26 | 3.74 | 2.36 | 13.9% | 80.5% |
Profit After Tax | 13.00 | 11.11 | 7.00 | 17.0% | 85.7% |
Earnings Per Share | 0.10 | 0.20 | 0.10 | -50.0% | 0.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Syncom Formulations (India) Ltd is a prominent entity within the pharmaceutical industry, primarily engaged in the manufacturing and marketing of a wide range of pharmaceutical formulations. The company focuses on delivering high-quality healthcare products, which include tablets, capsules, syrups, and ointments, catering to various therapeutic segments. As a part of its strategic initiatives, Syncom Formulations is known for its commitment to quality assurance and compliance with international standards, ensuring its products meet both domestic and global demands. Recent developments in the company, however, are not explicitly available within the provided data, and thus, specific recent activities or strategic changes cannot be outlined.
Revenue
In the third quarter of the fiscal year 2025 (Q3FY25), Syncom Formulations reported a total income of ₹131.57 crores, reflecting a significant increase from the previous quarter (Q2FY25) of ₹106.46 crores, marking a quarter-over-quarter (QoQ) growth of 23.6%. Comparatively, the year-over-year (YoY) growth from Q3FY24, where the total income was ₹69.69 crores, shows an impressive increase of 88.8%. These figures suggest a robust upward trajectory in revenue generation over both the quarterly and yearly periods. The consistent growth in total income aligns with the company's operational strategies aimed at enhancing market reach and product offerings in the pharmaceutical sector.
Profitability
The profitability of Syncom Formulations has demonstrated a positive trend, as evidenced by the profit before tax (PBT) for Q3FY25 amounting to ₹17.26 crores. This is a notable increase from ₹14.85 crores in Q2FY25, indicating a QoQ growth of 16.2%. When compared to the previous year (Q3FY24), where the PBT was ₹9.36 crores, there is an 84.4% YoY increase. The profit after tax (PAT) for Q3FY25 stands at ₹13.00 crores, up from ₹11.11 crores in Q2FY25, representing a QoQ rise of 17.0%. The YoY growth from Q3FY24, with a PAT of ₹7.00 crores, is 85.7%. This growth in profitability metrics underscores the company's efficiency in managing expenses relative to revenue growth.
Operating Metrics
Analyzing the operational expenses, the total expenses for Syncom Formulations in Q3FY25 were ₹114.31 crores, which increased from ₹91.61 crores in Q2FY25, reflecting a QoQ rise of 24.8%. Compared to Q3FY24, where expenses were ₹60.31 crores, there is an 89.5% YoY increase. Despite the rise in expenses, the company's profitability has improved, as indicated by the positive growth in profit metrics. Earnings per share (EPS) for Q3FY25 are reported at ₹0.10, showing a decrease from ₹0.20 in Q2FY25, indicating a -50.0% QoQ change, while maintaining the same level YoY from Q3FY24. This consistency in EPS YoY, despite fluctuations in quarterly performance, might suggest strategic decisions impacting shareholder returns.
